About 30 results found for searched term "STAT6-IN-2" (0.158 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M42113 | STAT6-IN-2 | STAT |
| STAT6-IN-2 is an inhibitor of STAT6. | ||
| M1711 | Febuxostat (TEI-6720) | Xanthine Oxidase |
| TEI-6720; Uloric; TMX-67 | ||
| Febuxostat (TEI-6720) is a non-purine selective xanthine oxidase inhibitor with IC50 of 114 -210 nM. | ||
| M2147 | Ilomastat | MMP |
| GM6001; Galardin | ||
| Ilomastat (GM6001; Galardin) is a broad spectrum matrix metalloprotease (MMP) inhibitor with Ki values of 0.4 nM, 0.5 nM, 27 nM, 3.7 nM, 0.1 nM, 0.2 nM, 3.6 nM, 13.4 nM and 0.36 nM for MMPs -1, -2, -3, -7, -8, -9, -12, -14 and -26, respectively. Ilomastat (GM6001; Galardin) reduces infarct volume following middle cerebral artery occlusion in an ischemic mouse model. | ||
| M2829 | Marimastat | MMP |
| BB2516; TA2516 | ||
| Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. | ||
| M5233 | Osilodrostat | Mineralocorticoid Receptor |
| LCI699 | ||
| Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. | ||
| M5259 | Citarinostat | HDAC |
| ACY-241 | ||
| Citarinostat (ACY-241) is an orally available selective HDAC6 inhibitor with IC50 of 2.6 nM and 46 nM for HDAC6 and HDAC3, respectively. It has 13 to 18-fold selectivity towards HDAC6 in comparison to HDAC1-3. | ||
| M5402 | Alvelestat (AZD9668) | Elastase |
| AZD9668 | ||
| Alvelestat (AZD9668) is an oral, highly selective inhibitor of neutrophil elastase (NE) with IC50 and Ki of 12 nM and 9.4 nM, at least 600-fold more selective over other serine proteases. | ||
| M6136 | Epacadostat | IDO |
| INCB024360 | ||
| Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). | ||
| M7539 | AS1517499 | STAT |
| AS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM. | ||
| M10532 | Tazemetostat hydrobromide | Histone Methyltransferase |
| EPZ-6438 hydrobromide; Tazemetostat HBr | ||
| Tazemetostat (EPZ-6438) hydrobromide is a first-in-class potent, selective and orally available EZH2 inhibitor. | ||
| M10746 | Denifanstat | FAS |
| TVB-2640; FASN-IN-2; ASC-40 | ||
| Denifanstat (TVB-2640) is an orally potent selective FASN inhibitor.IC50 to 0.052 μM,EC50 is 0.072 μM. Denifanstat has the potential to be used in fatty liver and cancer research. | ||
| M10968 | STAT5-IN-2 | STAT |
| STAT5-IN-2 is an inhibitor of STAT5 in K562 and KU812 cells EC50 9 μM and 5 μM respectively, the name in Document 1 is 17f. STAT5-IN-2 has highly effective antileukemia activity. | ||
| M11427 | RM-018 | Ras |
| INDEX NAME NOT YET ASSIGNED | ||
| RM-018 is an inhibitor of the active state of KRASG12C. Rm-018 retains the ability to bind and inhibit KRASG12C/Y96D. Rm-018 combines with GTP-bound to activate the [" RAS(ON) "] state of KRASG12C. | ||
| M14069 | Numidargistat dihydrochloride | Others |
| CB-1158 dihydrochloride; INCB01158 dihydrochloride | ||
| Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent. | ||
| M14297 | Fidarestat | Others |
| SNK 860 | ||
| Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease. | ||
| M15047 | Recombinant Mouse OSM (HEK 293) | Cytokines and Growth Factors |
| OncoM; oncostatin M | ||
| Protein Construction：OSM (Ala24-Arg206) Oncostatin M (OSM) is a multifunctional cytokine belonging to the interleukin-6 (IL-6) subfamily, which also includes IL-11, leukemia suppressor (LIF), ciliary nerve promoter, cardiac trophic factor-1 and novel nerve promoter factor-1. Protein structure: OSM (ALA24-ARG206), Accession # : P53347. | ||
| M15080 | Recombinant Human OSM (E.coli, N-6His) | Cytokines and Growth Factors |
| Oncostatin-M; OSM | ||
| Recombinant human Oncostatin M is produced by escherichia coli expression system, and the target gene encoding AlA26-ARG221 was expressed at the N-terminal with 6His marker. Measured by the dose-dependent stimulation of TF-1 cells. The ED50 for this effect is 0.2-1 ng/ml. | ||
| M20389 | Quisinostat (JNJ-26481585) 2HCl | HDAC |
| Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11 greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2. | ||
| M21381 | AS1810722 | STAT |
| AS1810722 is an orally effective STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows good CYP3A4 inhibition and is a thickened bicyclic pyrimidine derivative with potential for use in allergic disease studies, such as asthma and atopic diseases. | ||
| M28169 | Osilodrostat phosphate | Mineralocorticoid Receptor |
| LCI699 phosphate | ||
| Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. | ||
| M28540 | Talabostat | Dipeptidyl Peptidase |
| Val-boroPro; PT100 | ||
| Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities. | ||
| M28987 | Quabodepistat | Antibiotic |
| OPC-167832 | ||
| Quabodepistat (OPC-167832) is a potent and orally active dprE1 inhibitor with an IC50 of 0.258 μM. Quabodepistat has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis. | ||
| M29178 | Aclimostat | Others |
| ZGN-1061 | ||
| Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells. | ||
| M30035 | Spliceostatin A | Others |
| Spliceostatin A, the FR901464 methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells. | ||
| M30452 | TRPM4-IN-2 | TRP Channel |
| NBA | ||
| TRPM4-IN-2 (NBA) is a potent transient receptor potential melastatin 4 (TRPM4) inhibitor with an IC50 value of 0.16 μM. TRPM4-IN-2 can be used for researching prostate cancer and colorectal cancer. | ||
| M30649 | C188 | STAT |
| CPD188 | ||
| C188 is a STAT3 inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket. C188, in particular, was highly active in inducing apoptosis of the breast cancer cell line MB-MDA-468 in vitro (EC50= 0.7 μM). | ||
| M31278 | YM-341619 | STAT |
| AS1617612 | ||
| YM-341619 (AS1617612) is a potent, orally active STAT6 inhibitor with an IC50 value of 0.70 nM. It can be used in studies related to allergic diseases (e.g., asthma and atopic rhinitis) by selectively inhibiting the differentiation of CD4(+) T cells into the Th2 subpopulation, and thereby inhibiting the ability to inhibit allergen-induced Th2 responses. | ||
| M40707 | Icotrokinra | IL Receptor/Related |
| JNJ-2113; JNJ-77242113; PN-235 | ||
| Icotrokinra (JNJ-77242113, JNJ-2113) is a novel, orally active IL-23R peptide antagonist for studies related to plaque psoriasis. Icotrokinra exhibits high affinity with human IL-23 receptor hIL-23R with a Kd of 7.1 pM. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in PMBCs (IC50=5.6 pM), and inhibits L-23-induced generation of IFNγ and IL-17A in picomolar levels. | ||
| M41940 | PRL 3195 | Somatostatin Receptor |
| PRL 3195 is a somatostatin receptor antagonist with Kis of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst5, sst2, sst3, sst1 and sst4, respectively). | ||
| M49674 | PM-81I | STAT |
| PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
